Aigen Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-2,606
| Closed | -$613K | – | 742 |
|
|
2024
Q4 | $613K | Buy |
+2,606
| New | +$613K | 0.11% | 277 |
|
|
2024
Q2 | – | Sell |
-2,827
| Closed | -$422K | – | 750 |
|
|
2024
Q1 | $422K | Sell |
2,827
-21,717
| -88% | -$3.25M | 0.09% | 328 |
|
|
2023
Q4 | $4.7M | Buy |
+24,544
| New | +$4.7M | 0.84% | 7 |
|
|
2023
Q3 | – | Sell |
-26,604
| Closed | -$5.05M | – | 803 |
|
|
2023
Q2 | $5.05M | Buy |
26,604
+11,978
| +82% | +$2.28M | 0.75% | 14 |
|
|
2023
Q1 | $2.93M | Buy |
14,626
+7,767
| +113% | +$1.56M | 0.4% | 60 |
|
|
2022
Q4 | $1.63M | Buy |
6,859
+4,936
| +257% | +$1.17M | 0.23% | 123 |
|
|
2022
Q3 | $385K | Buy |
+1,923
| New | +$385K | 0.06% | 356 |
|
|
2022
Q2 | – | Sell |
-3,420
| Closed | -$558K | – | 515 |
|
|
2022
Q1 | $558K | Buy |
+3,420
| New | +$558K | 0.1% | 264 |
|
|
2021
Q3 | – | Sell |
-3,283
| Closed | -$557K | – | 459 |
|
|
2021
Q2 | $557K | Buy |
+3,283
| New | +$557K | 0.1% | 217 |
|